Market Volatility Continues to Drive Investor Interest in These 4 Companies

Sell in May and go away? Not so fast…

MIAMI, July 19, 2016 /PRNewswire/ — The last few weeks have been interesting ones to say the least. From the sociopolitical angst to the volatility that the stock market has seen, this summer has quickly become one to remember.

Sell in May and go away has not played to the benefit of those who assume the markets slow down or show less promise during the hotter months of the year.

This coming week may be no different either as expectations are buzzing on the flood of earnings results set to be reported. Furthermore, heading into this week, the Dow Jones Industrial Average and S&P 500 have both logged multiple all-time record highs and with indexes turning more bullish for the year second quarter earnings announcements could quickly add more fuel to the fire for summer bulls. This having been said, here are four stocks we will be watching closely on Monday:

IDdriven, Inc. (OTC: IDDR) (OTCQB: IDDR) has shown an impressive climb in stock price over the last few weeks. Following a climb to highs of $0.40 in June, the stock pulled back to as low as $0.179. Since hitting these lows, not only has the stock recovered by as much as 87% but the company’s latest announcements have shown to have a positive response in the market.

In response to the company’s most recent achievements with new channel partner PATECCO, Arend Verweij, IDdriven Chief Executive Officer, said, “IDdriven is building a solid foundation to support high volume, global sales to small, mid-size and large enterprises throughout Europe and the US. PATEECO is well known and highly respected for its expertise in all things IAM. We are delighted to partner with a world-class IAM expert that shares our commitment to excellence and unrivalled customer service.”

Rennova Health (NASDAQ: RNVA) recently saw a drastic gap down in price late last week. The trigger to this may have been from the announcement of a multi-million dollar offering that came out at a price of $0.45 per unit. However, since making the announcement and since the stock hit lows of $0.27, shares of RNVA have recovered after positive volume on Friday saw the stock close at a price of $0.30.

Rennova Health, Inc. owns and operates five diagnostics laboratories across the U.S. that provide clinical testing services specializing in toxicology testing for pain management clinics, drug and alcohol rehabilitation facilities and neurotransmitter testing. Rennova’s software is differentiated from that of its competitors by the breadth of its services, each of which is branded separately and is made available to physician groups in whole or in part.

expectations are buzzing on the flood of earnings results set to be reported

Other companies like Life Clips, Inc. (OTC: LCLP) (OTCQB: LCLP) that have seen all time highs this summer could be finding new opportunities during consolidation periods in price. Evidenced earlier this summer, LCLP saw several periods of consolidation, sometimes to the lower $0.40 range and has managed to see reversals in price to highs in the low $0.70 range. On Friday the stock closed at $0.48 after trading over 181,000 shares.

Most recently the company announced that it has broken ground in the Australian market for its one-time use, electronics charger called Mobeego. According to the company Mobeego®’s anticipated revenue before the end of Q3 of this year is $1,000,000. This morning Life Clips announced that it will be hosting a conference call to discuss current and future plans for the company.

Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is another stock that has been generating attention during the last few trading days. Similar to RNVA, the stock saw an aggressive drop off in price several weeks back when the company announced that it plans to discontinue its program in adult focal onset seizures and focus its efforts on advancing ganaxolone in status epilepticus and pediatric orphan indications. Since hitting lows of $1.23 in the days to follow the announcement, shares of MRNS have begun to climb in more recent weeks.

With the new focus for ganaxolone being pushed more toward status epliepticus and pediatric orphan indications, the recent spike in price and volume may be speculation based. The company has not announced any news since the end of June when it announced positive trends seen across multiple scales and the safety seen with ganaxolone in its Phase 2 trial for the treatment of anxiety and attention in children with Fragile X Syndrome (FXS). In fact, Friday the stock ended up hitting highs that it has not seen since dropping in mid June after seeing prices hit $2.23 during an active trading session.




DISCLAIMER: is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with or any company mentioned herein. The commentary, views and opinions expressed in this release by are solely those of and are not shared by and do not reflect in any manner the views or opinions of FNM. The companies that are discussed herein may or may not have approved the statements made in this release. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.